Related Experiment Video
Updated: Nov 23, 2025
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.7K
Undifferentiated prostate cancer treated with docetaxel
Masaki Kobayashi1, Minato Yokoyama1, Masaharu Inoue1
1Department of Urology Tokyo Medical and Dental University Tokyo Japan.
IJU Case Reports
|January 4, 2021
Summary
Docetaxel shows promise for treating advanced undifferentiated prostate cancer. This chemotherapy agent offered a partial response and extended survival in a patient with metastatic disease.
Area of Science:
- Oncology
- Prostate Cancer Research
Background:
- Undifferentiated prostate cancer is a rare, aggressive malignancy.
- No established treatment exists for metastatic undifferentiated prostate cancer.
Observation:
- A 70-year-old male patient presented with undifferentiated prostate cancer and lymph node metastases.
- The patient progressed despite platinum-based chemotherapy.
Findings:
- Docetaxel treatment led to a partial response in the patient.
- The patient survived for 42 months on docetaxel with good quality of life.
Implications:
- Docetaxel may be a viable therapeutic option for metastatic undifferentiated prostate cancer.
- Further investigation into docetaxel for this rare cancer subtype is warranted.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K